castle trial safety
Fix CASTLE Trial Issues with Chronic Disease Management
Fix CASTLE Trial Issues with Chronic Disease Management Over 90% of CASTLE trial participants experienced manageable side-effects, and 70% achieved sustained remission, showing CD19 CAR-T can be safely woven into chronic disease pathways for multiple sclerosis. Medical Disclaimer: This article is for informational purposes only and does not constitute medical